Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty: Two triple-switch case reports
Severe asthma affects between 5 and 10% of patients with asthma worldwide and requires best standard therapies at maximal doses. A subgroup of patients remains refractory to all treatments. We describe two case reports with severe allergic asthma who progressively worsened over the years despite the...
Main Authors: | Carlo Lombardi, Francesco Menzella, Giovanni Passalacqua |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | Respiratory Medicine Case Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007119302771 |
Similar Items
-
Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
by: Menzella F, et al.
Published: (2017-11-01) -
Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
by: Ryota Otoshi, et al.
Published: (2020-03-01) -
Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
by: Diego Bagnasco, et al.
Published: (2020-08-01) -
Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
by: Zafar Zafari, et al.
Published: (2016-01-01) -
Heat-induced necrosis after bronchial thermoplasty: a new concern?
by: Francesco Menzella, et al.
Published: (2018-06-01)